Summary of Study ST001391

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000954. The data can be accessed directly via it's Project DOI: 10.21228/M8CM3N This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files
Study IDST001391
Study TitleMetabolic Response in Patients with Post-Treatment Lyme Disease Symptoms/Syndrome
Study SummaryPost-treatment Lyme Disease Symptoms/Syndrome (PTLDS) occurs in approximately 10% of Lyme disease patients following antibiotic treatment. Objective biomarkers or specific clinical symptoms to identify PTLDS patients do not currently exist and the PTLDS classification is based on the report of persistent subjective symptoms for ≥ 6 months following antibiotic treatment for Lyme disease. Untargeted liquid chromatography-mass spectrometry metabolomics was used to define metabolic changes that occurred longitudinally in PTLDS and clinically cured non-PTLDS Lyme patients from two separate cohorts. An elastic net regularization model was applied to define the metabolites that classified PTLDS and non-PTLDS patients at different time points, and the PTLDS defining metabolites were evaluated in two sample cohorts using linear discriminant analysis. This study determined that observable metabolic alterations occur between PTLDS and non-PTLDS patients at multiple time points. These metabolic alterations discriminated between PTLDS and non-PTLDS patients and consisted of metabolites of glycerophospholipid, bile acid and acylcarnitine metabolism. Longitudinal analyses showed distinct patterns in metabolite abundance changes that indicated a greater variability in PTLDS vs non-PTLDS patients. These data provide evidence that an objective metabolite-based measurement can distinguish patients with PTLDS and help understand the underlying biochemistry of PTLDS.
Institute
Colorado State University
DepartmentDepartment of Microbiology, Immunology, and Pathology
LaboratoryBelisle
Last NameBelisle
First NameJohn
Address200 West Lake, Campus Delivery 0922, Colorado State University, Fort Collins, CO, 80523
Emailjohn.belisle@colostate.edu
Phone9704915384
Submit Date2020-05-28
Analysis Type DetailLC-MS
Release Date2020-09-21
Release Version1
John Belisle John Belisle
https://dx.doi.org/10.21228/M8CM3N
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR000954
Project DOI:doi: 10.21228/M8CM3N
Project Title:Metabolic Response in Patients with Post-Treatment Lyme Disease Symptoms/Syndrome
Project Summary:Sera from two small cohorts of patients were analyzed by untargeted liquid chromatography-mass spectrometry (LC-MS) to identify small molecule metabolites and metabolic pathways that differ between PTLDS and clinically cured (non-PTLDS) patients at baseline, following treatment completion and at one-year post-treatment.
Institute:Colorado State University
Last Name:Belisle
First Name:John
Address:200 West Lake, Campus Delivery 0922, Colorado State University, Fort Collins, CO, 80523, USA
Email:john.belisle@colostate.edu
Phone:9704915384

Subject:

Subject ID:SU001465
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Time point PTLDS
SA113205PTLDS_JHU_23BBaseline No
SA113206PTLDS_JHU_24BBaseline No
SA113207PTLDS_JHU_22BBaseline No
SA113208PTLDS_JHU_25BBaseline No
SA113209PTLDS_JHU_20BBaseline No
SA113210PTLDS_JHU_18BBaseline No
SA113211PTLDS_JHU_19BBaseline No
SA113212PTLDS_JHU_26BBaseline No
SA113213PTLDS_JHU_21BBaseline No
SA113214PTLDS_NYMC_2BBaseline No
SA113215PTLDS_NYMC_4BBaseline No
SA113216PTLDS_NYMC_1BBaseline No
SA113217PTLDS_NYMC_3BBaseline No
SA113218PTLDS_NYMC_5BBaseline No
SA113219PTLDS_NYMC_10BBaseline No
SA113220PTLDS_NYMC_7BBaseline No
SA113221PTLDS_NYMC_6BBaseline No
SA113222PTLDS_JHU_17BBaseline No
SA113223PTLDS_NYMC_8BBaseline No
SA113224PTLDS_JHU_16BBaseline No
SA113225PTLDS_NYMC_9BBaseline No
SA113226PTLDS_JHU_15BBaseline No
SA113227PTLDS_JHU_14BBaseline No
SA113228PTLDS_JHU_10BBaseline Yes
SA113229PTLDS_JHU_8BBaseline Yes
SA113230PTLDS_JHU_9BBaseline Yes
SA113231PTLDS_JHU_5BBaseline Yes
SA113232PTLDS_JHU_2BBaseline Yes
SA113233PTLDS_JHU_13BBaseline Yes
SA113234PTLDS_JHU_3BBaseline Yes
SA113235PTLDS_JHU_4BBaseline Yes
SA113236PTLDS_JHU_12BBaseline Yes
SA113237PTLDS_NYMC_12BBaseline Yes
SA113238PTLDS_JHU_11BBaseline Yes
SA113239PTLDS_NYMC_20BBaseline Yes
SA113240PTLDS_NYMC_21BBaseline Yes
SA113241PTLDS_NYMC_22BBaseline Yes
SA113242PTLDS_NYMC_19BBaseline Yes
SA113243PTLDS_NYMC_18BBaseline Yes
SA113244PTLDS_NYMC_13BBaseline Yes
SA113245PTLDS_NYMC_14BBaseline Yes
SA113246PTLDS_NYMC_15BBaseline Yes
SA113247PTLDS_NYMC_17BBaseline Yes
SA113248PTLDS_NYMC_11BBaseline Yes
SA113249PTLDS_JHU_6BBaseline Yes
SA113250PTLDS_JHU_1BBaseline Yes
SA113251PTLDS_NYMC_8OYFUOne-year follow-up No
SA113252PTLDS_NYMC_5OYFUOne-year follow-up No
SA113253PTLDS_JHU_24OYFUOne-year follow-up No
SA113254PTLDS_NYMC_10OYFUOne-year follow-up No
SA113255PTLDS_NYMC_6OYFUOne-year follow-up No
SA113256PTLDS_JHU_20OYFUOne-year follow-up No
SA113257PTLDS_NYMC_4OYFUOne-year follow-up No
SA113258PTLDS_JHU_19OYFUOne-year follow-up No
SA113259PTLDS_JHU_16OYFUOne-year follow-up No
SA113260PTLDS_NYMC_2OYFUOne-year follow-up No
SA113261PTLDS_JHU_17OYFUOne-year follow-up No
SA113262PTLDS_NYMC_1OYFUOne-year follow-up No
SA113263PTLDS_NYMC_3OYFUOne-year follow-up No
SA113264PTLDS_JHU_18OYFUOne-year follow-up No
SA113265PTLDS_JHU_21OYFUOne-year follow-up No
SA113266PTLDS_JHU_15OYFUOne-year follow-up No
SA113267PTLDS_JHU_26OYFUOne-year follow-up No
SA113268PTLDS_JHU_23OYFUOne-year follow-up No
SA113269PTLDS_JHU_14OYFUOne-year follow-up No
SA113270PTLDS_JHU_22OYFUOne-year follow-up No
SA113271PTLDS_NYMC_7OYFUOne-year follow-up No
SA113272PTLDS_JHU_25OYFUOne-year follow-up No
SA113273PTLDS_JHU_5OYFUOne-year follow-up Yes
SA113274PTLDS_NYMC_15OYFUOne-year follow-up Yes
SA113275PTLDS_JHU_1OYFUOne-year follow-up Yes
SA113276PTLDS_NYMC_21OYFUOne-year follow-up Yes
SA113277PTLDS_NYMC_17OYFUOne-year follow-up Yes
SA113278PTLDS_JHU_11OYFUOne-year follow-up Yes
SA113279PTLDS_JHU_10OYFUOne-year follow-up Yes
SA113280PTLDS_NYMC_20OYFUOne-year follow-up Yes
SA113281PTLDS_NYMC_12OYFUOne-year follow-up Yes
SA113282PTLDS_NYMC_19OYFUOne-year follow-up Yes
SA113283PTLDS_NYMC_18OYFUOne-year follow-up Yes
SA113284PTLDS_JHU_13OYFUOne-year follow-up Yes
SA113285PTLDS_NYMC_14OYFUOne-year follow-up Yes
SA113286PTLDS_JHU_12OYFUOne-year follow-up Yes
SA113287PTLDS_JHU_3OYFUOne-year follow-up Yes
SA113288PTLDS_JHU_8OYFUOne-year follow-up Yes
SA113289PTLDS_JHU_6OYFUOne-year follow-up Yes
SA113290PTLDS_JHU_4OYFUOne-year follow-up Yes
SA113291PTLDS_JHU_9OYFUOne-year follow-up Yes
SA113292PTLDS_NYMC_11OYFUOne-year follow-up Yes
SA113293PTLDS_JHU_17PTPost-treatment No
SA113294PTLDS_NYMC_1PTPost-treatment No
SA113295PTLDS_JHU_25PTPost-treatment No
SA113296PTLDS_NYMC_6PTPost-treatment No
SA113297PTLDS_JHU_21PTPost-treatment No
SA113298PTLDS_JHU_16PTPost-treatment No
SA113299PTLDS_JHU_24PTPost-treatment No
SA113300PTLDS_NYMC_8PTPost-treatment No
SA113301PTLDS_NYMC_2PTPost-treatment No
SA113302PTLDS_JHU_14PTPost-treatment No
SA113303PTLDS_NYMC_5PTPost-treatment No
SA113304PTLDS_JHU_20PTPost-treatment No
Showing page 1 of 2     Results:    1  2  Next     Showing results 1 to 100 of 135

Collection:

Collection ID:CO001460
Collection Summary:Sera (both cohorts) were collected at the time of diagnosis (baseline); at the completion of antibiotic therapy, approximately two to three weeks following diagnosis (post-treatment); and at one-year post-treatment (one-year follow-up). PTLDS (symptoms) patients were classified as such if symptoms developed at or within 6 months following diagnosis and persisted for at least 6 months following the completion of antibiotic therapy. Patients were classified as PTLDS (syndrome) if they met the above criteria and with daily life functional impairment reported.
Sample Type:Blood (serum)

Treatment:

Treatment ID:TR001480
Treatment Summary:N/A

Sample Preparation:

Sampleprep ID:SP001473
Sampleprep Summary:Serum samples were randomized prior to extraction of small molecule metabolites and LC-MS analyses. Metabolites were extracted with 75% methanol as previously described. Extracted metabolites were analyzed by LC-MS.
Sampleprep Protocol Comments:doi:10.1038/nprot.2011.335

Combined analysis:

Analysis ID AN002320
Analysis type MS
Chromatography type Reversed phase
Chromatography system Agilent 6520
Column Poroshell 120 EC-C8 (100 x 2.1mm,2.5um)
MS Type ESI
MS instrument type QTOF
MS instrument name Agilent 6520 QTOF
Ion Mode POSITIVE
Units counts

Chromatography:

Chromatography ID:CH001705
Instrument Name:Agilent 6520
Column Name:Poroshell 120 EC-C8 (100 x 2.1mm,2.5um)
Column Temperature:50
Flow Gradient:2-98% non-linear gradient
Flow Rate:0.25 ml/min
Solvent A:100% water; 0.1% formic acid
Solvent B:100% acetonitrile; 0.1% formic acid
Chromatography Type:Reversed phase

MS:

MS ID:MS002162
Analysis ID:AN002320
Instrument Name:Agilent 6520 QTOF
Instrument Type:QTOF
MS Type:ESI
MS Comments:LC-MS data were processed with MassHunter Profinder version B.08.00 and Mass Profiler Professional version B.14.9.01 (Agilent Technologies) to identify differentiating molecular features (MFs; metabolites defined by a retention time and accurate mass) between PTLDS and non-PTLDS patients at baseline, post-treatment and one-year follow-up in cohort-one. The biosignature-MFs determined using cohort-one were targeted in patient samples from cohort-two using MassHunter Profinder.
Ion Mode:POSITIVE
Capillary Voltage:4000
Dry Gas Flow:10 l/min
Dry Gas Temp:310
Fragment Voltage:120
Nebulizer:45 psi
Octpole Voltage:750 V
  logo